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Abstract
 
Although a pivotal role of proteasomes in the proteolytic generation of epitopes for major his-
tocompatibility complex (MHC) class I presentation is undisputed, their precise function is cur-
rently the subject of an active debate: do proteasomes generate many epitopes in definitive
form, or do they merely generate the COOH termini, whereas the definitive NH
 
2
 
 termini are
cleaved by aminopeptidases? We determined five naturally processed MHC class I ligands de-
rived from HIV-1 Nef. Unexpectedly, the five ligands correspond to only three cytotoxic T
lymphocyte (CTL) epitopes, two of which occur in two COOH-terminal length variants. Par-
allel analyses of proteasomal digests of a Nef fragment encompassing the epitopes revealed that
all five ligands are direct products of proteasomes. Moreover, in four of the five ligands, the
NH
 
2
 
 termini correspond to major proteasome cleavage sites, and putative NH
 
2
 
-terminally ex-
tended precursor fragments were detected for only one of the five ligands. All ligands are trans-
ported by the transporter associated with antigen processing (TAP). The combined results from
these five ligands provide strong evidence that many definitive MHC class I ligands are pre-
cisely cleaved at both ends by proteasomes. Additional evidence supporting this conclusion is
discussed, along with contrasting results of others who propose a strong role for NH
 
2
 
-terminal
trimming with direct proteasomal epitope generation being a rare event.
Key words: proteasome • HIV Nef • cytotoxic T lymphocyte epitopes • antigen processing • 
naturally processed peptides
 
Introduction
 
Proteasomes are the major cytosolic proteases of eukaryotic
cells and participate in the processing of many antigens pre-
sented by MHC class I molecules. However, the precise
role of proteasomes in epitope generation is not yet clear. It
is particularly a matter of debate whether proteasomes often
generate both COOH and NH
 
2
 
 termini of proteasome-
dependent epitopes, or whether they only generate their
COOH termini (1, 2).
Purified proteasomes degrade polypeptides into a large
number of extensively overlapping oligopeptides. Most
major peptide products of vertebrate 20S proteasomes have
hydrophobic, acidic, or basic amino acids (aa)
 
1
 
 at the
COOH terminus, most frequently leucine. Peptides with
other aa at the COOH terminus are produced less fre-
quently and are usually found in small amounts. With the
exception of acidic residues, which are found in protea-
some products but very rarely in MHC class I ligands, a
similar distribution of aa is observed at the COOH termini
of MHC class I ligands. Small neutral and polar aa, espe-
cially serine, are enriched at the NH
 
2
 
 termini of proteaso-
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Abbreviations used in this paper:
 
 aa, amino acid(s); ER, endoplasmatic retic-
ulum; FR, fluorescence ratio; IC
 
50
 
, 50% inhibition of specific binding;
LAP, leucine aminopeptidase; Nt, NH
 
2
 
-terminally; PA28, proteasome
activator 28; rp-HPLC, reversed phase HPLC; TAP, transporter associ-
ated with antigen processing; TPP II, tripeptidyl peptidase II. 
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mal products, also similar to MHC class I ligands (3–5). With
a few exceptions, the size range of peptides eluted from
typical MHC class I molecules is 7–13 aa, and most alleles
prefer nonamers (6). Although some peptides produced by
vertebrate 20S or 26S proteasomes from polypeptides or
proteins are shorter than 8 aa, only a few are larger than 11
aa (3, 4, 7), and many major products are in the size range of
MHC class I ligands (3, 4). Digestion of relatively short
polypeptides proceeds partially via single cleavage interme-
diates; formation of “dual cleavage” peptides, i.e., MHC
class I ligands and slightly longer peptides, is accelerated by
the IFN-
 
g
 
–inducible proteasome activator 28 (PA28 [4,
8]). Degradation of most full-length proteins is processive,
without the release of longer intermediates (9, 10). Of 10
MHC class I ligands examined so far in various laboratories
for production by purified proteasomes in vitro, 7 were
shown to be generated in definitive form (see Discussion).
Collectively, these data support the conclusion that protea-
somes produce both the COOH and NH
 
2
 
 termini of many
MHC class I ligands in vitro.
Nevertheless, these data have not led to a general con-
sensus on the precise role of proteasomes in antigen pro-
cessing. The validity of the in vitro results has been chal-
lenged by observations on the generation of the major
OVA epitope SIINFEKL from the products of minigenes
(11). Although the production of the epitope from COOH-
terminally (Ct)-extended versions was inhibited by the
proteasome inhibitor lactacystin, production from NH
 
2
 
-
terminally (Nt)-extended versions was not. Moreover, SI-
INFEKL could be produced from the Nt-extended frag-
ment QLESIINFEKL by leucine aminopeptidase (LAP), a
cytosolic peptidase inducible by IFN-
 
g
 
 (12). This was put
forward as evidence that the SIINFEKL NH
 
2
 
 terminus is
produced in vivo by trimming enzymes rather than by pro-
teasomes. Although these results can be interpreted in alter-
native ways (see Discussion), they have led to the general
perception that proteasomes mainly release the COOH ter-
mini of class I ligands, whereas the NH
 
2
 
 termini are derived
by trimming of longer precursors by aminopeptidases (1, 13).
Nef is a key factor in HIV pathogenicity and immunoge-
nicity and a potential candidate for CTL-targeted vaccina-
tion. More than 45 CTL epitopes for multiple HLA alleles
have been described in HIV Nef by the use of overlapping
synthetic peptides and/or “allele-specific” peptide motifs
(14). Many of the Nef CTL epitopes are overlapping, and
most of them cluster within four regions of the protein. To
date, naturally processed peptides corresponding to these
epitopes have not been determined. In this study we focused
on one of the four immunogenic regions of Nef, Nef
 
123–152
 
,
which is relatively conserved among different HIV subtypes
(15). We identified two HLA-A2 and three HLA-B7 pep-
tide ligands in this region. Unexpectedly, both HLA-A2
ligands and two of the three HLA-B7 ligands represented
COOH-terminal length variants of one HLA-A2 and one
HLA-B7 epitope, respectively. Proteolytic fragments iden-
tical to each of the five definitive MHC class I ligands were
found in proteasomal digests of the synthetic polypeptide
Nef
 
123–152
 
. In four of these five naturally processed peptides,
 
the NH
 
2
 
 123–152 were produced by major proteasome
cleavage sites, and Nt-extended precursors were found for
only one of the five peptides. Thus, at least four of the class I
ligands are loaded onto HLA molecules in the form generated
by proteasomes. These results favor the view that protea-
somes often produce the peptides finally presented by
MHC class I molecules.
 
Materials and Methods
 
Cell Lines. 
 
The human lymphoblastoid T cell lines T1 (HLA
class I typing A2, B5; subtyping for A2 is A
 
*
 
0201) and Jurkat
(HLA I typing A9/25, B7/41; subtyping for B7 is B
 
*
 
0702), the
HLA-A– and HLA-B–deficient C1R human lymphoblastoid B
cell lines transfected with HLA-A2 or HLA-B7 (C1R-A2 and
C1R-B7, respectively), and the P815 murine mastocytoma cell
lines transfected with HLA-A2 or HLA-B7 (P815-A2 and P815-
B7, respectively), have been described elsewhere (16–19). C1R-A2
and C1R-B7 cells were stably transfected with the pCF
 
1
 
 EBV
vector containing the sequence encoding the whole Nef protein
from the HIV-1 strain LAI under the control of the cytomega-
lovirus promoter (20). These cells, referred to as Nef
 
1
 
 C1R-A2
and Nef
 
1
 
 C1R-B7, were used as stimulator cells to induce poly-
clonal Nef-specific CTL lines and as target cells in experiments
with proteasome inhibitors. We were not able to maintain large
scale cultures of C1R-A2 and C1R-B7 cells stably expressing
Nef for acid elution of naturally processed peptides. For this pur-
pose, we used T1 and Jurkat cells transfected with the heavy
metal–inducible vector pSBBRU6e containing the sequence en-
coding the whole Nef protein from HIV-1 strain LAI, under the
control of the human metallothionein IIA promoter (21). These
cells are referred to as Nef
 
1
 
 T1 cells and Nef
 
1
 
 Jurkat cells. Ex-
pression of Nef in the transfectants was verified by Western blot
analysis. P815-A2 and P815-B7 cells were used as target cells
pulsed with peptides in cytotoxicity assays because C1R cells had
a high spontaneous 
 
51
 
Cr release. The human T1 line was used for
isolation of proteasomes.
 
In Vitro Induction of Primary Nef-specific CTL Lines. 
 
Polyclonal
Nef-specific CTL lines were induced as described (20) using PBLs of
a healthy HIV-1 seronegative donor (HLA class I typing A2/28, B7/
40w60, Cw3/w7; A2 and B7 subtypes are A
 
*
 
0201 and B
 
*
 
0702, re-
spectively) and Nef
 
1
 
 C1R-A2 or Nef
 
1
 
 C1R-B7 as stimulator cells.
Nef peptide–specific CTL lines were obtained from the same
donor (22). In brief, PBLs (4 or 5 
 
3
 
 10
 
6
 
) were incubated in 24-
well culture plates (Nalge Nunc International) using RPMI 1640
(GIBCO BRL) supplemented with 5% human AB serum (Blood
Donor Center Schweizerisches Rotes Kreuz [SRK], Basel, Swit-
zerland), 1 mM sodium pyruvate, 20 mM Hepes, 2 mM glutamine,
100 U/100 
 
m
 
g/ml penicillin/streptomycin (all from GIBCO
BRL), 1 
 
3
 
 10
 
2
 
5
 
 M 2-ME (Sigma Chemical Co.), and 1% MEM
nonessential amino acids (GIBCO BRL) for 90 min at 37
 
8
 
C. The
nonadherent cells were removed, and the adherent fraction (mono-
cytes) was pulsed with 100 
 
m
 
g/ml of peptide for 4 h to be used as
stimulator cells. Adherent cells were then incubated with 1 
 
3
 
 10
 
6
 
autologous PBLs. After 5 d of culture, 100 U/ml proleukin (Chiron
Corp.) was added. After an additional 7 d, the PBLs were restimu-
lated with 1 
 
3
 
 10
 
5
 
 irradiated autologous PHA (Murex Biotech,
Ltd.) T cell blasts, pulsed with 10 
 
m
 
g/ml of peptide.
 
Cytotoxicity Assay. 
 
Cytolytic activity was tested in triplicate
in a standard 4-h 
 
51
 
Cr-release assay (23). Activity was assayed
against cells expressing Nef as well as against P815-A2 and P815-
B7 cells pulsed with synthetic peptides or reversed phase HPLC 
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(rp-HPLC) fractions containing naturally processed peptides or
proteasomal products. To study the effect of proteasome inhibi-
tors, the Nef-expressing cells were incubated in the presence of
10 
 
m
 
M lactacystin (Dr. E.J. Corey, Harvard Medical School,
Boston, MA) or 100 
 
m
 
M 
 
N
 
-acetyl-leucinyl-leucinyl-norleucinal
(LLnL; Sigma Chemical Co.) for 2 h before 
 
51
 
Cr labeling. The
cells were then radiolabeled, and the preexisting peptide–MHC
class I complexes on the cell surface were removed by exposure
to a quick acid wash (131 mM citric acid, 66 mM disodium
phosphate, pH 3.1) at 25
 
8
 
C for 3 min (24). After neutralization in
30 vol of complete RPMI 1640 medium and washing in PBS,
cells were plated and used as targets in a 4-h 
 
51
 
Cr-release assay in
either the presence or absence of the inhibitors.
 
Synthetic Peptides. 
 
Peptides were either synthesized using
solid phase 9-fluorenylmethoxycarbonyl (F-moc) chemistry on
an Applied Biosystems 431A peptide synthesizer or purchased
from Genosys Biotechnologies. Peptides were purified to 
 
.
 
98%
homogeneity by rp-HPLC. Amino acid residues are given in sin-
gle-letter code as follows: C, Cys; D, Asp; E, Glu; F, Phe; G,
Gly; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R,
Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
 
Extraction of Naturally Processed Peptides. 
 
Naturally processed
peptides were extracted from whole cells with TFA (25) and pu-
rified as described previously (26, 27). Batches of 10
 
9
 
 Nef
 
2
 
 T1,
Nef
 
1
 
 T1, Nef
 
2
 
 Jurkat, and Nef
 
1
 
 Jurkat cells were lysed by add-
ing 15 ml cold 1% TFA (Sigma Chemical Co.) and disrupted us-
ing a hand-held glass homogenizer. Centriprep 10K (Amicon Corp.)
centrifugal concentrators were used for isolation of low molecular
weight peptides. The ultrafiltrate suspensions (molecular weight
 
,
 
10 kD) were dried by lyophilization and redissolved in 0.1%
TFA for fractionation by rp-HPLC.
 
In Vitro Digestion of Polypeptide Substrate by Purified 20S Protea-
somes. 
 
20S proteasomes were purified from human T1 cells as
described previously (4). No impurities were detected by SDS or
native gel electrophoresis. Tripeptidyl peptidase II (TPP II) con-
taminations were excluded by use of the TPP II inhibitors AAF-
chloromethylketone (Bachem) and PMSF (Sigma Chemical Co.).
Digestion of the synthetic 30-mer polypeptide Nef
 
123–152
 
 (10 
 
m
 
g)
with isolated 20S proteasomes (2 
 
m
 
g) was carried out at 37
 
8
 
C.
Digests were incubated in a total volume of 300 
 
m
 
l buffer consist-
ing of 50 mM Tris-HCl (pH 7.8), 1 mM EGTA, 0.5 mM
EDTA, 5 mM MgCl
 
2
 
, 0.5 mM 2-ME, and 0.02% azide. Aliquots
of the reaction mixture were fractionated by rp-HPLC.
 
rp-HPLC Fractionation and Analysis of Natural and Synthetic Pep-
tides. 
 
Aliquots of rp-HPLC fractions were separated by
 
 
 
rp-HPLC
(Smart System [Amersham Pharmacia Biotech]) equipped with a
Sephasil C18 SC2.1/10 column) with the following: eluent A,
0.1% TFA; eluent B, 80% acetonitrile containing 0.081% TFA;
flow rate, 100 
 
m
 
l/min; gradient for separation of HLA-A2–
restricted peptides, 34.3–35.5% B in 55 min (increase of eluent B,
0.022% per min); gradient for separation of HLA-B7–restricted
peptides, 23.5–24.4% B in 28 min (increase of eluent B, 0.032%
per min) followed by 24.4–26.5% B in 27 min (increase of 0.078%
per min). Fractions were collected from 30 to 85 min (fractions
1–59), and elution was monitored by measuring UV light absorp-
tion at 214 nm in a continuous flow detector. TFA/acetonitrile
was removed from the eluted fractions by lyophilization. The
lyophilized material was redissolved in 200 
 
m
 
l PBS and stored at
 
2
 
70
 
8
 
C. Aliquots of the rp-HPLC fractions were assayed for rec-
ognition by specific CTLs in a 
 
51
 
Cr-release assay. Aliquots of the
rp-HPLC fractions from proteasomal digestions were directly an-
alyzed with a G2025A matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometer (Hewlett-Pack-
 
ard) and by Edman degradation on a Hewlett-Packard instrument
(model G1000A).
 
The Transporter Associated with Antigen Processing–Peptide Binding
Assay. 
 
The affinity of peptides for the transporter associated
with antigen processing (TAP) was measured essentially as de-
scribed previously (28), using microsomes purified from Sf9 in-
sect cells expressing human TAP1–TAP2 complexes, iodinated re-
porter peptide RRYNASTEL, and a dilution series of competitor
test peptides. The concentrations required for 50% inhibition of
specific binding (IC
 
50
 
) were normalized with respect to the IC
 
50
 
 of
the reporter peptide (typically 
 
z
 
400 nM). The results are expressed
as relative IC
 
50
 
 and are mean values from three experiments.
 
MHC Class I–Peptide Binding Assay. 
 
The HLA binding ability
of the HLA-B7–restricted peptides was measured by HLA-B7
stabilization on the TAP-deficient hybrid cell line T2-B7 (29). In
brief, cells were incubated with 100, 50, 25, and 12.5 
 
m
 
M of pep-
tide in serum-free medium at 37
 
8
 
C. Staining for indirect immuno-
fluorescence was performed with ME1 (anti-B7, -Bw22, and -B27)
as first antibody, and FITC-labeled anti–mouse IgG (Sigma Chemi-
cal Co.) as second antibody. Fluorescence intensities were mea-
sured on a FACScan™ cytometer (Becton Dickinson). The fluo-
rescence ratio was calculated as the mean fluorescence of the
sample versus the mean fluorescence of the control. The synthetic
reference peptide used was the HLA-B7–restricted self-peptide
(APRTVALTAL). The peptide Nef
 
198
 
LHPEYFKNC
 
206
 
, which
does not bind to HLA-B7, was used as negative control.
Peptide affinity for immunoaffinity-purified HLA-A2 mole-
cules was measured in a competitive binding assay based on pub-
lished procedures (30). In brief, HLA-A2 molecules were purified
from NP-40 lysates of the homozygous B cell line Jesthorn using
Sepharose-immobilized BB7.2 (anti-A2) mAb. Purified HLA-A2
molecules (400 ng) were incubated for 18 h with 2.4 pmol of iodi-
nated reporter peptide hepatitis B virus (HBV) core 18–27 (6Y)
and various concentrations of unlabeled competitor peptides in a
total volume of 30 
 
m
 
l PBS buffer with 0.05% NP-40 and 1 mM
PMSF. Peptide binding was stopped and evaluated by a 4-min
centrifugation at 25
 
8
 
C and 1,000 
 
g
 
 through gel filtration columns
(Micro Bio-Spin 30™; Bio-Rad Laboratories). Bound peptide was
quantified by gamma counting of filtrates. The results are expressed
as relative IC
 
50
 
 and are mean values from three experiments.
 
Quantitation of MHC Class I Ligands in Nef-transfected Cells.
 
The molar concentrations of MHC ligands in rp-HPLC fractions
of acid eluates of Nef-transfected cells were determined by titra-
tion of rp-HPLC fractions in a 4-h 
 
51
 
Cr-release assay, and com-
parison of the percent specific lysis was obtained with a standard
curve of known concentrations of synthetic peptide. The molar
amounts of peptide ligands obtained per extraction were multi-
plied by Avogadro’s number and divided by the number of cells
that were extracted. Recoveries of control synthetic peptides
were determined as described (26).
 
Results
 
Effect of Proteasome Inhibitors on Intracellular Nef Processing.
 
Lactacystin is an efficient inhibitor of the chymotrypsin-
and trypsin-like activities of proteasomes (31), and a weaker
inhibitor of the cytoplasmic protease complex TPP II (32).
To assess whether proteasomes are involved in the process-
ing of Nef, we studied the effect of lactacystin on the HLA-
A2– and HLA-B7–restricted presentation of Nef, using
concentrations that discriminate between proteasomes and
TPP II. Nef
 
1
 
 C1R-A2 and Nef
 
1
 
 C1R-B7 cells were incu- 
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bated for 2 h in the presence of 10 
 
m
 
M lactacystin and then
briefly exposed to pH 3.1 to denature and remove surface
class I peptide complexes. Acid-stripped target cells were
then allowed to reexpress MHC class I–peptide complexes
for 4 h during a standard 
 
51
 
Cr-release assay, in the presence
or absence of 10 
 
m
 
M lactacystin. In the absence of lactacys-
tin, target cell lysis by HLA-A2– and HLA-B7–restricted
Nef-specific CTLs was restored after acid treatment (Fig. 1),
reaching 80–100% of the lysis of untreated target cells (data
not shown). Incubation of acid-treated cells with lactacys-
tin completely abrogated the restoration of HLA-A2– and
HLA-B7–restricted CTL recognition of Nef epitopes (Fig. 1).
CTL recognition of acid- and lactacystin-treated target cells
was restored by addition of known HLA-A2– or HLA-B7–
binding Nef peptides, excluding nonspecific deterioration
of target cells or of CTLs by the experimental procedures
(Fig. 1). A similar degree of inhibition was observed with
the peptide aldehyde inhibitor N-acetyl-leucinyl-leucinyl-
norleucinal, another potent but less specific proteasome in-
hibitor (data not shown). These results suggested that pro-
cessing of Nef for presentation by HLA-A2 as well as
HLA-B7 MHC molecules was dependent on proteasomes.
 
Design of the Experiments. 
 
One of the four immunogenic
regions of Nef (Nef
 
123–152
 
, Table I) was chosen for this study.
One HLA-A2 (Nef
 
136
 
PLTFGWCYKL
 
145
 
) and two HLA-B7
(Nef
 
128
 
TPGPGVRYPL137 and Nef135YPLTFGWCY143) re-
stricted CTL epitopes in this region have been identified
previously, using polyclonal Nef-specific CTLs from HIV-
seropositive donors and target cells pulsed with overlapping
Nef peptides or Nef epitopes predicted according to allele-
specific motifs (34, 35, 37). We now wanted to determine
the naturally processed peptides corresponding to these
epitopes. For acid elution from Nef-transfected cells, large-
scale cell cultures of Nef-expressing cells were necessary.
Because of the cytotoxic effect of Nef, attempts to prepare
large-scale cultures of cells stably transfected with Nef have
Figure 1. Effect of lactacystin on recog-
nition of HLA-A2– and HLA-B7–restricted
HIV-1 Nef-derived epitopes by Nef-spe-
cific CTL lines. 51Cr-labeled C1R-A2 (left)
and C1R-B7 (right) cells, untransfected
(Nef2) or transfected (Nef1), were preincu-
bated for 2 h in the presence of 10 mM lac-
tacystin. Cell surface MHC class I–peptide
complexes were then removed by acid
treatment (see Materials and Methods). The
cells were washed and used as target cells in
a 4-h 51Cr-release assay in the absence (j)
or presence of 10 mM lactacystin (n). The
Nef-specific CTL line was generated from
PBLs of an uninfected seronegative donor
after in vitro stimulation with Nef1 C1R-
A2 or Nef1 C1R-B7, as described in Ma-
terials and Methods. Reconstitution of lac-
tacystin-treated Nef1 C1R-A2 cells was
achieved by pulsing with the A2-restricted HIV-1 Nef136PLTFGWCYKL145 peptide and reconstitution of Nef1 C1R-B7 cells by pulsing with the B7-
restricted HIV-1 Nef128TPGPGVRYPL137 peptide (m). Nef2 C1R-A2 and Nef2 C1R-B7 cell lines were included as negative controls (u). The results
are representative of three independent experiments.
Table I. CTL Epitopes Previously Predicted by Epitope Mapping with Synthetic Peptides and/or Peptide–HLA Binding Assays in the 123–152 
Region of Nef of HIV-1 LAI
Position Sequence* HLA class Reference
126–138 NYTPGPGVRYPLT B7 33
128–137 TPGPGVRYPL B7 34, 35
130–143 GPGVRYPLTFGWCY B57 36
132–147 GVRYPLTFGWCYKLVP A1, B8, B18, B49 37, 38
133–148 VRYPLTFGWCYKLVPV B57 39
134–143 RYPLTFGWCY B18, B49 37
134–144 RYPLTFGWCYK B18, B49 37, 40
135–143 YPLTFGWCY B7, B18, B49 37
135–144 YPLTFGWCYK B18, B49 37
136–145 PLTFGWCYKL A2.1 35
*The single-letter amino acid code is used.243 Lucchiari-Hartz et al.
rarely been successful (41, 42). To overcome these problems,
we used a regulated Nef expression vector (pSBBRUnef)
based on a mutated version of the heavy metal–inducible
human metallothionein IIA promoter. T1 (HLA class I typ-
ing A2, B5) and Jurkat (HLA I typing A9/25, B7/41) cells
transfected with this vector produce low basal levels of Nef
compatible with large-scale cultures (21). Several liters of ei-
ther T1 or Jurkat cells stably transfected with pSBBRUnef
were grown, followed by induction of Nef expression for
24 h. Peptides were isolated by acid extraction of cell ly-
sates followed by ultrafiltration (10-kD cutoff).
In parallel, a synthetic polypeptide corresponding to the
region Nef123–152 was digested with 20S proteasomes iso-
lated from T1 cells. Both peptide pools, that of the acid-
extracted naturally processed peptides and that obtained upon
proteasomal digestion of Nef123–152, were separated under
the exact same conditions by rp-HPLC on an analytical
C18 column. Fractions obtained were tested for their abil-
ity to sensitize target cells expressing the appropriate MHC
class I restriction elements for recognition by Nef peptide–
specific CTL lines. To identify the relevant peptides in frac-
tions recognized by CTLs, retention times were compared
with those of a series of synthetic Nef-derived overlapping
peptides recognized by the same CTLs (Figs. 2 and 3, arrows).
To achieve efficient separation of such closely related pep-
tides, extremely shallow TFA/acetonitrile gradients were
used, individually adjusted for the analysis of each of the
epitopes under study (see Materials and Methods). To as-
certain that peptides identified in acid-eluted fractions were
indeed Nef-derived MHC ligands, control lysates of cells
Figure 2. Comparison between HLA-A2–restricted naturally processed HIV-1 Nef peptides and products derived from in vitro 20S proteasomal degrada-
tion of the synthetic polypeptide HIV-1 Nef123–152. Acid-soluble extracts prepared from Nef1 T1 cells and peptide products derived from 20S proteasome–
mediated degradation of the synthetic 30-mer polypeptide Nef123–152 were fractionated by rp-HPLC using a very shallow TFA/acetonitrile gradient (see Ma-
terials and Methods). Individual fractions were tested for their ability to sensitize P815-A2 cells for lysis by CTL lines specific for the peptides
Nef136PLTFGWCYKL145 (A) and Nef136PLTFGWCYKLV146 (B) in a 4-h 51Cr-release assay. Acid-soluble extracts from Nef2 T1 cells fractionated before
the eluate of Nef1 T1 cells (A and B, top left), or mock rp-HPLC fractions (buffer only) collected before fractionation of the proteasomal products (A and B,
bottom left), gave no activity. The A2-restricted Nef136PLTFGWCYKL145 peptide–specific CTL line did not lyse P815-A2 cells pulsed with peptides eluted
from HLA-A22, Nef1 Jurkat cells (A, top left). CTL assays were carried out using an E/T ratio of 50:1 (A and B, left) or at different E/T ratios as indicated
(A and B, right). The elution position of synthetic peptides is indicated by arrows. The results are representative of five independent experiments.244 Proteasomal Generation of HIV Nef Epitopes
not transfected with Nef and from Nef-transfected cells
lacking the MHC molecule in question were fractionated
using the same gradient and tested by the same CTLs.
Comparison between HLA-A2–restricted Naturally Processed
Nef Peptides and Peptides Derived from Proteasomal Degradation
of the 30-mer Nef123–152 Polypeptide. Fractions obtained upon
rp-HPLC separation of acid extracts of A21, Nef1 T1 cells
were tested for the ability to sensitize HLA-A21 target cells
for lysis by HLA-A2–restricted CTL lines induced against
the peptide Nef136PLTFGWCYKL145 (Fig. 2 A, top). Sur-
prisingly, Nef136PLTFGWCYKL145-specific CTLs recog-
nized not only fractions coeluting with the synthetic peptide
Nef136PLTFGWCYKL145 (fraction 21/22), but also fractions
coeluting with the synthetic peptide Nef136PLTFGWCYKLV146
(fractions 33–35). Accordingly, a CTL line was generated
by stimulation with Nef136PLTFGWCYKLV146. As shown
in Fig. 2 B (top), these CTLs also recognized fractions con-
taining Nef136PLTFGWCYKL145, as well as fractions contain-
ing Nef136PLTFGWCYKLV146. Neither CTL line recog-
nized peptide material eluted from Nef2 T1 cells (Fig. 2, A
[top] and B [top]) or peptides eluted from A22, Nef1 Jurkat
cells (Fig. 2 A, top left; data for Nef136PLTFGWCYKLV146-
specific CTLs not shown). These controls indicate that the
acid-eluted peptides recognized by both CTL lines were
Nef derived and specifically associated with HLA-A2 mol-
ecules of the T1 cells. Moreover, and unexpectedly, the re-
sults suggest that the two peptides represent two naturally
processed versions of the same epitope, differing in length
by one COOH-terminal aa.
In parallel, a digest of Nef fragment123–152 was prepared
with isolated proteasomes, fractionated, and analyzed by the
same protocol (Fig. 2, A [bottom] and B [bottom]). Strik-
ingly, both CTL lines recognized the exact same rp-HPLC
fractions as in the Nef1 T1 cell extracts (fractions 21/22
and 33–35). Active fractions identified in the Nef1 T1 cell
extracts and in the products derived by proteasomal diges-
tion and corresponding control fractions were reexamined
with serial dilutions of the CTLs, confirming the single E/T
ratio results of individual fractions (Fig. 2, A [right] and B
[right]). These results strongly suggested that the HLA-A2–
restricted CTL epitopes detected in material eluted from
Nef-transfected cells were identical to those epitopes iden-
tified in the proteasomal digest.
Comparison between HLA-B7–restricted Naturally Processed Nef
Peptides and Peptides Derived from Proteasomal Degradation of the
30-mer Nef123–152 Polypeptide.  To identify HLA-B7–
restricted  naturally processed Nef peptides, peptides were acid
eluted from B71, Nef1 Jurkat cells and fractionated by
rp-HPLC. Fractions were first screened with an HLA-B7–
restricted CTL line generated against Nef128 TPGPGVRYPL137.
Again surprisingly, Nef128TPGPGVRYPL137-specific CTLs
recognized two rp-HPLC fractions of acid-eluted material:
fraction 3 corresponding to the elution time of Nef128
TPGPGVRY135, and fraction 15 corresponding to the elu-
tion time of Nef128TPGPGVRYPL137 (Fig. 3 A, top). Ac-
cordingly, CTLs were prepared against the smaller peptide,
the octamer Nef128TPGPGVRY135, and these were found
to recognize the same two fractions (Fig. 3 B). These re-
sults suggest that the two peptides represent two naturally
processed versions of the same epitope, differing in length
by two COOH-terminal aa.
Peptides eluted from Nef-transfected Jurkat cells were also
screened with a CTL line against Nef135YPLTFGWCY143.
This CTL line recognized a single fraction of naturally pro-
cessed peptides (fraction 23), corresponding to the elution
time of the inducing peptide (Fig. 3 C, top). This suggests
that Nef135YPLTFGWCY143 is indeed a naturally processed
peptide, and that this epitope exists only in one HLA-B7–
binding version. However, the epitope overlaps extensively
with the HLA-A2–binding naturally processed peptides
Nef136PLTFGWCYKL145 and Nef136PLTFGWCYKLV146
described in the previous section. All three HLA-B7–
restricted Nef peptide–specific CTL lines failed to recognize
peptide material eluted from Nef2 Jurkat cells or HLA-
B72, Nef1 T1 cells, indicating that the peptides eluted from
Nef-transfected Jurkat cells were Nef derived and specifically
bound to HLA-B7 molecules (Fig. 3 B, top left).
In parallel, proteasomal digests of Nef123–152 were separated
by rp-HPLC using the exact same gradients. Each of the
three HLA-B7–restricted CTL lines recognized fractions
identical to that of the acid-eluted peptides (Fig. 3, A–C;
compare top and bottom). Active fractions identified in the
Nef-transfected Jurkat cell extracts and in the products de-
rived by proteasomal digestion and corresponding control
fractions were reexamined with serial dilutions of CTLs,
confirming the single E/T ratio results of individual frac-
tions (Fig. 3, A [right] and B [right]). These results suggest
that the peptides recognized by the three HLA-B7–restricted
CTLs in acid eluates of Nef-transfected Jurkat cells and in
proteasomal digests of Nef123–152 were identical.
Comprehensive Analysis of Peptide Fragments Generated by
Digestion of Nef123–152 with Purified Proteasomes In Vitro.  The
proteasomal digest of Nef123–152 was separated by rp-HPLC
using a relatively steep gradient to recover the vast majority
of all possible fragments (Fig. 4 A). The peptides produced
were identified by mass spectrometry and Edman degrada-
tion. Fig. 4 B shows a digestion map compiling all identi-
fied degradation products and proteasomal cleavage sites,
the strength of the latter according to the quantification of
the adjacent products by Edman degradation. All of the five
naturally processed peptides detected by CTLs (see above)
could also be found by protein analytical methods. The
HLA-B7–binding octamer peptide Nef128TPGPGVRY135
is the major dual cleavage product, presumably because it is
flanked by predominant cleavage sites and very little cleav-
age occurs internally. The remaining four peptides suffer
more pronounced internal cleavage and are thus produced
in smaller, but still considerable amounts. It is remarkable
that significant quantities of the HLA-B7 ligands Nef128
TPGPGVRYPL137 and Nef135YPLTFGWCY143 are pro-
duced upon proteasomal digestion, as both peptides are
subject to destruction by the predominant cleavage site in
the polypeptide Y135-P136. This major cleavage site gener-
ates the COOH terminus of the abundant HLA-B7–bind-
ing octamer Nef128–135 as well as the NH2 termini of the
two naturally processed HLA-A2 ligands. Most signifi-245 Lucchiari-Hartz et al.
cantly, in four of the five naturally processed peptides (Nef128
TPGPGVRY135, 128TPGPGVRYPL137, 136PLTFGWCYKL145,
and 136PLTFGWCYKLV146), the NH2 termini correspond
to major proteasomal cleavage sites.
Peptide Binding to TAP and MHC Class I Molecules.  The
results described above strongly suggest, but do not directly
prove, that each of the five acid-eluted peptides are also
successfully translocated by TAP and bind to MHC class I.
To directly address affinity for TAP, binding assays were
performed using microsomes isolated from insect cells ex-
pressing human TAP1–TAP2 complexes (28). Relative af-
finities (IC50 values) measurable in this assay range from 0.1
to 3,000. Peptides with IC50 values .3,000 are excluded
from translocation into the endoplasmatic reticulum (ER
[43]). The IC50 values suggest a slightly higher TAP-bind-
ing affinity for the two HLA-A2 ligands than for the three
Figure 3. Comparison be-
tween HLA-B7–restricted natu-
rally processed HIV-1 Nef pep-
tides and products derived from
in vitro 20S proteasomal degra-
dation of the synthetic polypep-
tide HIV-1 Nef123–152. Acid-sol-
uble extracts prepared from Nef1
Jurkat cells and peptide products
derived from 20S proteasome–
mediated degradation of the
synthetic 30-mer polypeptide
Nef123–152 were fractionated by
rp-HPLC using a very shallow
TFA/acetonitrile gradient (see
Materials and Methods). Individ-
ual fractions were tested for their
ability to sensitize P815-B7 cells
for lysis by CTL lines specific for
peptides Nef128TPGPGVRYPL137
(A), Nef128TPGPGVRY135 (B),
or Nef135YPLTFGWCY143 (C)
in a 4-h 51Cr-release assay.
Acid-soluble extracts from Nef2
Jurkat cells fractionated before
the eluate of Nef1 Jurkat cells
(A, B, and C, top left), or mock
rp-HPLC fractions (buffer only)
collected before fractionation of
the proteasomal products (A, B,
and C, bottom left), gave no ac-
tivity. The B7-restricted Nef128
TPGPGVRY135 peptide–specific
CTL lines did not lyse P815-B7
cells pulsed with peptides eluted
from HLA-B72, Nef1 T1 cells
(B, top left). CTL assays were
carried out using an E/T ratio of
50:1 (A, B, and C, left) or at dif-
ferent E/T ratios as indicated (A,
B, and C, right). The elution po-
sition of synthetic peptides is in-
dicated by arrows. The results
are representative of five inde-
pendent experiments.246 Proteasomal Generation of HIV Nef Epitopes
HLA-B7 ligands (Table II). Of note, all five HLA-binding
peptides have a proline in either position 1 or 2, a situation
thought to be unfavorable for TAP transport (28, 44, 45).
Nevertheless, IC50 values for all five peptides were in the
range consistent with moderately efficient TAP transport
(Table II).
The five HLA ligands were also tested for their ability to
bind to their MHC class I restriction elements (Table II).
For the two HLA-A2 ligands, this was done by a competi-
tion assay using immunoaffinity-purified HLA-A2 molecules.
For the three HLA-B7 ligands, stabilization of HLA-B7 on
the surface of HLA-B7–transfected T2 cells was deter-
mined by flow cytometry. As expected, MHC class I bind-
ing could be shown for all five peptides. The results for
both the HLA-A2 and HLA-B7 ligands suggest binding af-
finities somewhat below that of the high affinity peptides
used as positive control in the assays. Together, the TAP-
and MHC-binding data would predict low to moderate ef-
ficiencies of presentation for all five of the Nef-derived
HLA ligands.
Estimation of Epitope Copy Numbers Per Cell.  On the ba-
sis of the results of the TAP- and MHC-binding assays, low
to intermediate copy numbers of presented epitopes were
predicted for all five of the peptides. The molar concentra-
tions of the peptides recognized in acid-eluted rp-HPLC
fractions were estimated in CTL assays in which each fraction
was tested in serial dilutions in parallel with known molar
concentrations of the same synthetic peptide. Examples are
shown in Fig. 5. Total molecules of recovered peptides were
calculated from the molarities, and copy numbers of the pep-
tides per cell could then be estimated (Table II). According to
these calculations, the HLA-B7 ligand Nef128TPGPGVRY135
appears to be present in high copy numbers comparable to
the most efficiently presented MHC class I ligands known.
Intermediate copy numbers are calculated for the second
HLA-B7 ligand, Nef128TPGPGVRYPL137, whereas the re-
maining three peptides appear at low copy numbers. The
exceptionally efficient presentation of Nef128TPGPGVRY135
cannot be accounted for by exceptionally high values for
TAP transport or MHC class I binding. However, Nef128
TPGPGVRY135 is by far the most abundant dual cleavage
fragment in the proteasomal digest (see Fig. 4). This epitope
may thus represent another example for a significant influ-
ence of proteasomes on epitope hierarchy.
Discussion
Although it is undisputed that the COOH termini of
proteasome-dependent epitopes are predominantly gener-
ated by proteasomal cleavage, it is controversial whether
proteasomes also contribute significantly to liberation of the
NH2 termini of MHC class I ligands (1). Here we describe
five naturally processed MHC class I binding peptides of
HIV-1 Nef, corresponding to three different CTL epitopes.
These are the first naturally processed peptides ever identified
in HIV Nef. In contrast to previous reports on this subject,
our study concerns not only a single but also a cohort of de-
terminants derived, in addition, from a highly relevant anti-
gen. Four results in combination strongly suggest the genera-
tion of these determinants by proteasomes without assistance
of other proteases: (a) all five ligands studied were produced
in definitive form by proteasomes in digests of the fragment
HIV-1 Nef123–152 (this paper) as well as of recombinant full-
length Nef (Lucchiari-Hartz, M., N. Hitziger, K. Eichmann,
and G. Niedermann, manuscript in preparation); (b) the
NH2 termini of four of the five ligands correspond to major
proteasomal cleavage sites; (c) Nt-extended proteolytic frag-
ments were found in proteasomal digests for only one of the
five definitive ligands; and (d) all five peptides were trans-
ported by TAP.
Figure 4. Digestion by 20S proteasomes of the synthetic 30-mer
polypeptide HIV-1 Nef123–152. A synthetic peptide corresponding to the se-
quence Nef123–152 was incubated with proteasomes isolated from human T1
cells (see Materials and Methods). The peptide mixture obtained after sub-
strate consumption was separated by rp-HPLC, and individual fractions
were analyzed by mass spectrometry and Edman degradation. (A) rp-HPLC
chromatogram obtained upon separation of the proteasomal digest of the
30-mer Nef123–152. The sequence of the peptides contained in the major
peaks is indicated in single-letter code. The Nef HLA-A2–binding ligands,
136PLTFGWCYKL145  and  136PLTFGWCYKLV146,  as well as the Nef
HLA-B7–binding ligands, 128TPGPGVRY135, 128TPGPGVRYPL137, and
135YPLTFGWCY143, are indicated by asterisks. (B) Digestion map compil-
ing all identified degradation products (indicated as lines underneath the se-
quence; the five MHC class I ligands are shown in bold) and proteasomal
cleavage sites (indicated by arrows). The strength of proteasomal cleavage
was estimated from quantification of the adjacent products by Edman deg-
radation. The six arrow sizes indicate increasing amounts of peptides flank-
ing each cleavage site as follows: undetectable by Edman degradation; 10,
10–50, 50–150, 150–500, and 500 pmol peptide.247 Lucchiari-Hartz et al.
Unexpectedly, four of the five ligands represent COOH-
terminal length variants of only one HLA-B7– (8- and 10-
mer) and one HLA-A2–binding epitope (10- and 11-mer),
respectively. To our knowledge, this is the first description
of length variants of CTL epitopes from a non–self-antigen.
However, since length variants were seen for two out of
three CTL epitopes, this observation might not be excep-
tional. In both cases, CTL lines induced with the short and
the long variant peptide showed CTL cross-recognition of
both peptide length variants. However, since we did not
analyze CTLs on the clonal level, it cannot be excluded
that CTLs with exclusive specificity for the inducing pep-
tide are also induced. The length variants described here
are COOH-terminal length variants. Thus, our finding is
in agreement with the notion that there is apparently no
COOH-terminal trimming activity in the ER (46, 47), and
also no evidence for effective COOH-terminal trimming
activity in the cytosol (12). Recognition of the longer vari-
ants by CTLs was not dependent on extracellular trimming
by carboxypeptidases present in FCS (data not shown).
Two binding modes for class I ligands slightly longer than
canonical peptides have been described: they either pro-
trude beyond the COOH-terminal end of the MHC class I
peptide binding groove (48) or are fixed at the COOH ter-
minus and bulge out in the middle (49, 50). Since we ob-
serve extensive CTL cross-recognition, we favor the former
binding mode for the longer epitope variants in both of our
pairs of class I ligands as being more likely to be compatible
with conserved conformation of the central peptide resi-
dues critical for TCR recognition.
In four of the five ligands, the NH2 termini coincide
with major proteasome cleavage sites. In the case of all five
ligands, not only the COOH-terminal aa, but also the aa in
the flanking position N minus 1, are preferred P1 residues2
of proteasomes (either tyrosine, leucine, valine, or arginine).
Four ligands have small or polar aa in the NH2-terminal
(P19) position of proteasomal cleavage sites. The major
cleavage site that creates the COOH terminus of the abun-
dant octamer HLA-B7–binding epitope and the NH2 ter-
minus of the two HLA-A2 ligands has a valine in position
P3. Small and/or polar P19 residues and hydrophobic P3
residues can promote proteasomal cleavage at the P1–P19
site (3, 4, 10, 51). The NH2-terminal two thirds of the
HLA-B7 ligand Nef128TPGPGVRY135, the sequence of
which is identical with the NH2-terminal flanking region
of the two HLA-A2 ligands and of the HLA-B7 ligand
Nef135YPLTFGWCY143, contains only proline, glycine,
and threonine. These residues are extremely disfavored
P1 residues of proteasomes (3, 10) conferring protection
against proteasomal cleavage.
Four HLA ligands had low to moderate affinities for hu-
man TAP, whereas the 136PLTFGWCYKLV146 HLA-A2
ligand had a slightly higher TAP affinity. All five ligands
have proline in either position 1 or 2. It has been recog-
nized previously that prolyl residues in positions 1, 2, or 3
are generally unfavorable for TAP translocation (28, 44, 45,
52). In such cases, it has been proposed that NH2-terminal
Table II. Characteristics of HIV-1 Nef CTL Epitopes Described in This Study
Peptide Sequence
Relative IC50 for
TAP*
MHC class I
binding
No. of MHC I
ligands per cell‡
HLA-A2
Relative IC50
§
Nef136–145 PLTFGWCYKL 49 295 85
Nef136–146 PLTFGWCYKLV 17 75 125
HLA-B7
FRi
Nef128–135 TPGPGVRY 160 30 3,600
Nef128–137 TPGPGVRYPL 195 25 840
Nef135–143 YPLTFGWCY 304 18 80
*The unlabeled Nef peptides were used to compete the binding of 125I-labeled RRYNASTEL (used at 240 nM) to TAP1/2 insect cell microsomes.
The average IC50 of the reporter peptide in these assays was 400 nM. All values are normalized by dividing IC50 for test peptides by the IC50 of un-
labeled reporter peptide measured in the same assay.
‡The number of Nef ligands per Nef1 T1 cell (HLA-A2 restriction) and Nef1 Jurkat cell (HLA-B7 restriction) was estimated as described in Mate-
rials and Methods (see also Fig. 5). Numbers given are corrected for extraction yields. Extraction yields: Nef136–145 (69%), Nef136–146 (74%), Nef128–135
(88%), Nef128–137 (95%), and Nef135–143 (50%).
§The unlabeled Nef peptides were used to compete the binding of 125I-HBV core 18–27 (6Y) to HLA-A2 molecules. The average IC50 of the re-
porter peptide in these assays was 80 nM. All values are normalized by dividing IC50 of unlabeled reporter peptide measured in the same assay.
iPeptide binding to HLA-B7 class I molecules on T2-B7 cells was measured by enhanced surface expression of these molecules (see Materials and
Methods). FRs obtained at 100 mM of peptide concentration are shown. FR for Nef198LHPEYFKNC206 (negative control) 5 8, for the HLA-
B7–restricted self-peptide APRTVALTAL (positive control) 5 45.
2The nomenclature for the amino acid residues of protease substrates with
respect to the scissile bond is P3-P2-P1—cleavage site—P19-P29-P39.248 Proteasomal Generation of HIV Nef Epitopes
extension can improve TAP affinity, and that the final class
I ligands may be produced by trimming of epitope precur-
sors in the ER (52, 53). However, we have recently pre-
sented evidence suggesting that even for presentation by
HLA-A2, which is suboptimally adapted to TAP, antigen
processing may favor peptides that do not require ER pro-
cessing (43, 45). For the two HLA-A2 ligands and for two
of the three HLA-B7 ligands identified in this study, Nt-
elongated precursor peptides were not found among the
proteasomal products. One of the potential precursors of
the HLA-B7–binding octamer Nef128TPGPGVRY135 was
the nonamer YTPGPGVRY. However, this nonamer is
generated in lower amounts than the octamer. In addition,
it has a proline in position 3 and should therefore not be
preferred in TAP transport. The 10-mer NYTPGPGVRY
and the 12-mer WQNYTPGPGVRY might have higher
TAP affinity because they lack a prolyl residue in positions
1–3. Although these peptides are generated in significantly
smaller amounts than the octamer, a contribution of NH2-
terminal trimming of these putative precursors in the ER is
presently not excluded and needs to be evaluated. The only
proteasomal fragment that could represent an Nt-elongated
precursor of the HLA-B7–binding 10-mer ligand Nef128
TPGPGVRYPL137 was a single cleavage product starting
with the NH2-terminus of the 30-mer substrate. A similar
single cleavage intermediate was found in significant
amounts for the HLA-B7–binding octamer. However, these
single cleavage intermediates were not found in digests of
full-length Nef (Lucchiari-Hartz, M., N. Hitziger, K. Eich-
mann, and G. Niedermann, manuscript in preparation) and
most probably result from the limited length of the sub-
strate used here. Together, our data suggest that at least
four of the five HLA-A2 and HLA-B7 ligands identified
here are translocated into the ER predominantly in their
definitive form, despite suboptimal TAP transport. We have
shown previously that peptides with similar TAP affinities
can even be very efficiently presented when abundantly
generated (43). Of note, it has been shown that even the
highly restrictive mouse TAP translocates peptides with
unfavorable COOH-terminal residues in amounts suffi-
cient for T cell recognition. The selective TAP influence
became detectable only at limiting cytosolic peptide con-
centrations (54).
Several previous studies showing that MHC class I
ligands may be direct major products of 20S proteasomes
and/or proteasome–PA28 complexes were concerned with
highly selected examples, i.e., the high copy self-peptides
SYFPEITHI and TLWVDPYEV, derived from the cellular
tyrosine kinase Janus kinase (JAK) 1, and the product of the
B cell translocation gene 1, respectively (4, 8, 55), or the im-
munodominant OVA epitope SIINFEKL (3, 4, 56). Slightly
longer precursor peptides that could be candidates for NH2-
terminal trimming were either not found or were produced
in low quantities in these cases. A second group of MHC
ligands was shown to be generated by proteasomes as mi-
nor products. The Ld ligand YPHFMPTNL derived from
the pp89 protein of the murine cytomegalovirus and the
subdominant OVA epitope KVVRFDKL are produced by
proteasomes, albeit in small amounts, whereas Nt-extended
peptides are more efficiently produced (3, 8, 57, 58). A
p53-derived and a b-galactosidase–derived class I ligand
could also be detected in proteasomal digests of a source
polypeptide and the source protein, respectively, albeit only
with the highly sensitive use of specific CTLs (27, 56).
Three further reports describe unsuccessful attempts to de-
tect epitopes in proteasomal digests: the KSPWFTTL pep-
tide derived from the p15E protein of the AKV/MCF type
of murine leukemia virus (53), the vesicular stomatitis virus
nucleoprotein–derived epitope RGYVYQGL (59), and the
peptide IPGLPLSL derived from the c-akt protooncogene
Figure 5. Titration of the defined HIV-1 Nef–derived HLA-B7
ligands (synthetic peptides) and rp-HPLC fractions of acid-eluted Nef1
Jurkat cells. P815-B7 targets were pulsed with the indicated concentra-
tions of peptide, and cytotoxicity assays were performed using the follow-
ing Nef peptide–specific CTL lines generated from donor PR3 (see Ma-
terials and Methods): (A) 128TPGPGVRY135-specific CTLs; (B)
128TPGPGVRYPL137-specific CTLs; and (C) 135YPLTFGWCY143-spe-
cific CTLs. As negative control, target cells were incubated with medium
only. The E/T ratio was 100:1.249 Lucchiari-Hartz et al.
(60). In these cases, only slightly longer peptides were found
by protein analytical methods. However, in one of these
studies, minor products have not been analyzed (60). Fur-
thermore, the exact NH2 terminus of human melanoma
antigen (MAGE)3271–179 is liberated by proteasomes. Nev-
ertheless, the epitope is cryptic, because its COOH termi-
nus is normally not liberated by proteasomes. However,
crypticity of this epitope is abolished in the presence of lacta-
cystin, since lactacystin-treated proteasomes generate the
epitope COOH terminus in addition to its NH2 terminus
(61). Together, these data suggest that proteasomes often pro-
duce the final MHC class I ligands, albeit in varying amounts.
Therefore, the available data have not led to a general con-
sensus on the role of proteasomes in antigen processing.
The notion that epitope NH2 termini may frequently re-
sult from nonproteasomal cleavage in vivo stems primarily
from a study on the generation of SIINFEKL in cells trans-
fected with minigenes. Although production of the epitope
from Ct-extended versions was inhibited by 2 or 20 mM
lactacystin, that from Nt-extended versions was not (11).
This finding may have an alternative explanation. The pep-
tide bond at the SIINFEKL NH2 terminus is hydrolyzed
efficiently by purified 20S proteasomes and proteasome–
PA28 complexes (3, 4, 56). Since the SIINFEKL NH2 ter-
minus is directly preceded by glutamic acid (E), cleavage of
the E256-S257 bond is most likely dependent on the post-
glutamyl activity of the proteasome. This activity is only
marginally and competitively inhibited by lactacystin, i.e.,
only partially even at excessive lactacystin concentrations
(62). Thus, it is to be expected that proteasomal generation
of the SIINFEKL NH2 terminus is poorly inhibited by lac-
tacystin. Moreover, it is unlikely that the extraordinarily
rapid hydrolysis by proteasomes at this site is efficiently
blocked by any competitive inhibitor.
Along the same line, it was proposed that the SIINFEKL
NH2 terminus is produced by LAP, a cytosolic aminopepti-
dase inducible by IFN-g. Small amounts of SIINFEKL
were shown to be produced upon prolonged incubation of
synthetic QLESIINFEKL with cytosol preparations from
IFN-g–treated cells, or by purified LAP (12). We think
that this study potentially overemphasizes a minor mecha-
nism in the generation of SIINFEKL. This epitope is ex-
cised by purified proteasomes from partial or total OVA in
7–10-fold greater amounts than QLESIINFEKL (3, 56). In
addition, SIINFEKL is resistant against proteasomal attack
once generated (3). In contrast, SIINFEKL is degraded
when incubated with LAP (our unpublished data). Thus, the
production of SIINFEKL via QLESIINFEKL by a two-step
digestion involving aminopeptidases is likely to be a minor
pathway. In addition, TPP II, which was inadvertently de-
pleted from the cytosol in the protocol used by Beninga et al.
(12), is a strong candidate for the generation of SIINFEKL via
the QLESIINFEKL precursor.
We do not mean to exclude that precursor trimming (at
least NH2-terminal trimming) also contributes to MHC
class I ligand formation. The steric constraints on peptide
extensions at the NH2 terminus of the class I peptide bind-
ing groove appear to be stricter than on peptide extensions
at the COOH terminus (63). In accordance with that fact,
alignments of eluted class I ligands (6) and MHC–peptide
affinity measurements (64) suggest that stable complex for-
mation between class I MHC molecules and Nt-extended
peptides may not occur normally, although there may be
exceptions (65). These stringent requirements for correct
NH2 termini in MHC class I ligands are compatible with a
trimming activity generating suitable termini. This activity
may act in cases where proteasomes do not generate the
correct NH2 terminus of a class I ligand. Moreover, trim-
ming may often contribute to ligand formation when elon-
gated peptides are produced by proteasomes in addition to
the minimal ligands, especially when such precursors have
significantly higher TAP affinities than the minimal epitopes.
Indeed, experimental evidence for NH2-terminal trimming
capacity has been reported in the cytosol (12) and in the
ER for both signal peptide–coupled epitope precursors (11,
66–68) and a TAP-translocated peptide (43). However, it
remains to be determined whether the generation of an
epitope by two distinct proteases is as efficient as the gener-
ation of an epitope by proteasomes alone.
Nef is a major virulence factor of HIV and simian immu-
nodeficiency virus (SIV), and appears to be critical for the
development of AIDS (69–71). Among other biological ef-
fects, Nef downregulates MHC class I expression in HIV-
infected and Nef-transfected cells (72), and was suggested to
partially protect HIV-infected primary CD41 T cells against
recognition by HLA-A2–restricted HIV-Gag and HIV re-
verse transcriptase–specific CTL clones (73). On the other
hand, there is also strong evidence that CD81 lymphocytes
play an important role in controlling viremia in SIV and HIV
infections (74, 75). An effective HIV vaccine should therefore
be designed to elicit CTL responses. Before the present re-
port, only two naturally processed CTL epitopes of HIV
were known, one for Gag and the other for reverse tran-
scriptase (26). In view of the MHC downregulation by Nef,
it may be mandatory to target CTL vaccines to epitopes that
are presented in high copy numbers, such as the HLA-B7–
restricted naturally processed Nef peptide, 128TPGPGVRY135,
identified in this paper. Nef is synthesized at the earliest
stage of viral gene expression and is abundantly expressed
(76). High anti-Nef CTL responses have been detected in
the acute and asymptomatic phases as well as later in HIV
infection (35, 77, 78), and high frequencies of CTL precur-
sors have been found in noninfected individuals (20). A de-
tailed knowledge of MHC class I–peptide ligands and their
intracellular generation, as well as the molecular basis of the
adverse effects of Nef, should be instrumental in the devel-
opment of an HIV vaccine including Nef CTL epitopes.
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